Mifepristone (RU-486) Availability in India: Legal & Medical Context

Mifepristone (RU-486), the antiprogestin used for medical abortion, is NOT approved or legally marketed in India. The Central Drugs Standard Control Organization (CDSCO) has not granted marketing authorization. This creates a critical gap in reproductive healthcare access.

Legal Framework for Abortion in India

Medical Termination of Pregnancy (MTP) Act, 1971 (amended 2002, 2021):

• Gestational limits: Up to 20 weeks (general); 24 weeks (special categories: rape, incest, minors, disability, fetal anomaly); no limit (substantial fetal anomaly, medical board)
• Providers: Registered Medical Practitioners (RMPs) with MTP training
• Facilities: Approved hospitals/clinics (District Level Committee certification)

Current Practice: Surgical Dominance

Without mifepristone, India relies almost entirely on surgical methods:

• Manual Vacuum Aspiration (MVA): Up to 12-14 weeks. Portable, electricity-independent, 98% effective.
• Electric Vacuum Aspiration (EVA): Up to 12-14 weeks. Clinic-based.
• Dilation & Evacuation (D&E): 14-24 weeks. Higher skill, complication risk.
• Misoprostol-only regimens: Used off-label (800 mcg vaginal/buccal/sublingual, repeat). Less effective (75-85% ≤12 wks), more side effects, unpredictable completion.

Why Mifepristone Matters

WHO Essential Medicine since 2005. Combined with misoprostol: 95-98% effective ≤12 weeks, non-invasive, self-manageable (with guidance), reduces facility burden, expands access for rural/marginalized women.

Barriers to Introduction

• Regulatory inertia: CDSCO requires local clinical trials (costly, time-consuming) despite global evidence
• Political sensitivity: Abortion stigma, sex-selection fears (PCPNDT Act 1994), moral objections
• Pharmaceutical economics: Off-patent, low margin — limited commercial incentive
• Misoprostol-only entrenchment: Cheap, available (ulcer indication), "good enough" for many providers

Recent Developments

• 2021 MTP Amendment: Expanded gestational limits, recognized "failure of contraception" — increased demand for medical options
• FOGSI (Ob/Gyn Federation) Advocacy: Formal CDSCO submissions (2022, 2023) for mifepristone approval
• ICMR Studies: Operational research on medical abortion feasibility in public system
• Compassionate Use: Some states (Kerala, Tamil Nadu) pilot mifepristone+miso in public facilities via special approvals

Access Reality

Women seeking medical abortion often: (1) Obtain misoprostol-only from pharmacies (schedule H, sold without prescription), (2) Travel to Nepal/Bangladesh/Sri Lanka where combipack available, (3) Use unsafe methods. Estimated 15.6M abortions/yr (Guttmacher 2015); ~78% outside facilities.

Bottom Line: India's abortion law is relatively liberal, but the absence of mifepristone — the global gold standard — forces reliance on surgical methods and suboptimal misoprostol-only regimens, disproportionately harming poor, rural, and marginalized women. Regulatory approval remains the critical bottleneck.